Table 2.

Subgroup analysis of the pooled HRs for OS and PFS in cancer patients with PD-L1 expressed in the CTCs

	OS			PFS
	Number of studies Heterogeneity I2%, p	Pooled HRs (95% CI)	Interaction (p)	Number of studies Heterogeneity I2%, p	Pooled HRs (95% CI)	Interaction (p)
Total	43.1(0.055)	1.96(1.34–2.88)	0.001	64.7(0.000)	1.50 (1.12–2.01)	0.007
Cutoff
>1	32.5(0.227)	2.74(1.63–4.60)	0.000	57.8(0.037)	1.37(0.83–2.24)	0.217
≤1	0.0(0.543)	1.82(1.22–2.74)	0.004	24.2(0.244)	1.85(1.26–2.72)	0.002
unknown	64.3(0.061)	0.9(0.32–2.54)	0.835	78.3(0.000)	1.19(0.48–2.98)	0.710
Median Age
>65	77.2(0.012)	1.37(0.27–7.06)	0.707	82.9(0.001)	0.59(0.16–2.12)	0,417
≤65	33.7(0.171)	1.74(1.18–2.56)	0.005	15.3(0.303)	1.82(1.35–2.45)	0.000
unknown	0.0(0.587)	2.67(1.31–5.45)	0.007	67.3(0.009)	1.85(0.90–3.80)	0.093
Area
America	0.0(0.652)	2.39(1.62–3.52)	0.000	67.4(0.005)	1.17(0.51–2.66)	0.707
Australia	-	-	-	82.7(0.003)	1.08(0.16–7.24)	0.938
China	0.0(0.440)	3.03(1.61–5.72)	0.001	0.0(0.924)	2.85(1.93–4.20)	0.000
France	0.0(0.625)	1.23(0.68–2.21)	0.494	0.0(0.788)	1.29(0.84–1.97)	0.239
Greece	69.9(0.068)	1.43(0.40–5.05)	0.579	38.8(0.195)	1.32(0.84–2.08)	0.231
Tumor type
Gastrointestinal cancer	0.00(0.459)	2.99(1.68–5.30)	0.000	0.0(0.859)	2.86(1.61–5.09)	0.000
Lung cancer	39.1(0.145)	1.64(1.07–2.51)	0.022	53(0.010)	1.36(1.00–1.84)	0.047
Treatment method
ICI	70.1(0.018)	1.31(0.46–3.75)	0.618	66.9(0.000)	1.41(0.67–2.96)	0.370
No ICI	18.0(0.288)	2.02(1.44–2.83)	0.000	65.7(0.000)	1.55(1.08–2.23)	0.018
Data types
Multivariate	73.4(0.010)	1.18(0.46–3.02)	0.728	75.4(0.017)	0.74(0.26–2.11)	0.575
Others	0.0(0.572)	2.15(1.57–2.94)	0.000	64.5(0.000)	1.71(1.21–2.42)	0.002